PPARA and fatty liver disease: Treatment with a specific PPARα agonist, Wy 14,634, in various mouse models with metabolic deregulations such as lipoatrophic diabetes [28], spontaneous fatty liver in the absence of obesity or T2D [29], NAFLD [30] and NASH [31] resulted in improved dyslipidaemia, insulin resistance and hepatic steatosis.